Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 1/20 | 0.46 |
| ▸ | TK1 | P04183 | 3/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570200 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2RNASE1TYMSTK1 | |
| SCHEMBL24595722 | 0.92 | LMNA (0.55) | LMNASMN1; SMN2RNASE1TYMSTK1 | |
| SCHEMBL6852678 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2RNASE1TK1 | |
| SCHEMBL16311910 | 0.89 | LMNA (0.57) | LMNASMN1; SMN2RNASE1TYMSTK1 | |
| SCHEMBL13026818 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2RNASE1TK1 | |
| SCHEMBL6374113 | 0.89 | LMNA (0.67) | LMNASMN1; SMN2RNASE1TK1 | |
| SCHEMBL12969271 | 0.88 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278968 | 0.88 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL22143532 | 0.88 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 | |
| SCHEMBL4278972 | 0.88 | RNASE1 (0.61) | RNASE1TK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4599404-A | BENOYLATION | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1986-07-08 | — | — | US | claimed |
| EP-0009882-A1 | 2'-Deoxy-5-fluorouridine derivatives, a process for producing the same and antitumor agents comprising the same | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1980-04-16 | — | — | EP | claimed |
| JP-56113795-A | — | — | None | — | — | JP | disclosed |
| JP-55035057-A | — | — | None | — | — | JP | disclosed |
| US-8916536-B2 | Bone-targeting bisphosphonate duplex drugs | SCHOTT HERBERT (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2601202-B1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | SCHOTT HERBERT (DE) | 2013-09-12 | — | — | US | disclosed |
| US-5869464-A | HAVING LOW TOXICITY, SUSTAINING LOW CONCENTRATION IN BLOOD FOR EXTENDED PERIOD | TAIHO PHARMACEUTICAL CO. LTD. (JP) | 1999-02-09 | — | — | US | disclosed |
| EP-0686641-B1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG | TAIHO PHARMACEUTICAL CO LTD (JP) | 1998-08-26 | — | — | EP | disclosed |
| EP-0686641-A1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PROCESS FOR PRODUCING THE SAME, AND ANTITUMOR DRUG | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-4599404-A | BENOYLATION | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1986-07-08 | — | — | US | disclosed |
| US-4503045-A | ORAL ADMINISTRATION | FUNAI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1985-03-05 | — | — | US | disclosed |
| US-4490366-A | 2'-Deoxy-5-fluorouridine derivative and a process for producing the same and an antitumor agent comprising the same | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1984-12-25 | — | — | US | disclosed |
| US-4425335-A | ANTITUMOR | FUNAI KAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1984-01-10 | — | — | US | disclosed |
| US-4416875-A | ANTITUMOR AGENTS | FUNAI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1983-11-22 | — | — | US | disclosed |
| EP-0009882-B1 | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR PRODUCING THE SAME AND ANTITUMOR AGENTS COMPRISING THE SAME | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1982-03-03 | — | — | EP | disclosed |
| JP-S56113795-A | 2'-DEOXY-3',5'-DI-O-ACETYL-5-FLUOROURIDINE DERIVATIVE, ITS PREPARATION AND ANTITUMOR AGENT CONTAINING THE SAME | FUNAI CORP | 1981-09-07 | — | — | JP | disclosed |
| EP-0009882-A1 | 2'-Deoxy-5-fluorouridine derivatives, a process for producing the same and antitumor agents comprising the same | FUNAI PHARMACEUTICAL IND., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
| JP-S5535057-A | 2'-DEOXY-5-FLUOROURIDINE DERIVATIVE, ITS PREPARATION, AND ANTITUMOR AGENT COMPRISING IT | FUNAI CORP | 1980-03-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237494-A1 | BONE-TARGETING BISPHOSPHONATE DUPLEX DRUGS | BPGM, MVD, PPIP5K2 | LMNA 3664/4885SMN1; SMN2 3596/4885RNASE1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.